Further studies are required to clarify the mechanism for the regulation of UCP2 in BAT under HFD conditions, since UCP is a promising therapeutic target for the treatment of obesity and obesity-related diseases. Here, UCP2 is linked to obesity due to melanocortin 4 receptor deficiency.